)
Overview
<ul>
<li>Biopharmaceutical firm’s Q3 revenue drops to $2 mln from $9 mln yr-ago</li>
<li>Posts Q4 net loss vs profit in year-ago quarter</li>
<li>Roivant reported $4.5 bln in cash and marketable securities as of Dec 31, 2025</li>
</ul>
Outlook
<ul>
<li>Roivant plans Phase 3 study for brepocitinib in cutaneous sarcoidosis starting in 2026</li>
<li>Company expects topline data from brepocitinib NIU trial in second half of 2026</li>
<li>Roivant actively exploring additional indications for brepocitinib</li>
</ul>
Result Drivers
<ul>
<li>R&amp;D EXPENSES - Increase in R&amp;D expenses driven by program-specific costs and share-based compensation</li>
<li>STRONG CASH POSITION - Reported $4.5 bln in cash and marketable securities as of Dec 31, 2025</li>
</ul>
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 $2 mln
Revenue
<h3>Q3 EPS -$0.38</h3>
Q3 Net -$313.70
Income mln
Q3 Miss -$339.15 -$306.38
Income mln mln (6
From Analysts
Operatio )
ns
<h3>Q3 $341.15</h3>
Operatin mln
g
Expenses
Analyst Coverage
<ul>
<li>The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 11 “strong buy” or “buy”, 1 “hold” and no “sell” or “strong sell”</li>
<li>The average consensus recommendation for the pharmaceuticals peer group is “buy”</li>
<li>Wall Street’s median 12-month price target for Roivant Sciences Ltd is $26.00, about 23% above its February 5 closing price of $21.14</li>
</ul>
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Reuters

SPDR S&P Biotech

iShares US Pharma

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Direxion S&P Biotech Bear 3X

Invesco Biotechnology & Genome ETF

VG Health

iShares Biotechnology ETF

iShares Global Healthcare

Roivant Sciences

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Roivant swings to Q3 loss as revenue drops